
    
      Gemtuzumab ozogamicin in combination with busulfan and cyclophosphamide (immunochemotherapy)
      conditioning followed by allogeneic stem cell transplantation + anti-thymocyte globulin
      (unrelated donors only) in patients with high risk CD33+AML or MDS meeting eligibility
      criteria.
    
  